inclusion criteria: individuals who: 1. are able to give consent 2. must have completed study arct-021-01 3. agree to comply with all study visits and procedures only for subjects that will receive arct-021 in this study: 4. are healthy and medically stable 5. are not planning to donate blood or plasma until 28 days after the last dose of arct-021. 6. are willing to refrain from strenuous exercise/activity and alcohol for at least 72 hours prior to study visits and until 28 days after the last dose of arct-021. 7. are willing to adhere to contraception requirements if sexually active and/or are of child-bearing potential

inclusion criteria: individuals who: 1. are able to give consent 2. must have completed study arct-021-01 3. agree to comply with all study visits and procedures only for subjects that will receive arct-021 in this study: 4. are healthy and medically stable 5. are not planning to donate blood or plasma until 28 days after the last dose of arct-021. 6. are willing to refrain from strenuous exercise/activity and alcohol for at least 72 hours prior to study visits and until 28 days after the last dose of arct-021. 7. are willing to adhere to contraception requirements if sexually active and/or are of child-bearing potential

inclusion criteria: individuals who: are able to give consent must have completed study arct-021-01 agree to comply with all study visits and procedures only for subjects that will receive arct-021 in this study: are healthy and medically stable are not planning to donate blood or plasma until 28 days after the last dose of arct-021. are willing to refrain from strenuous exercise/activity and alcohol for at least 72 hours prior to study visits and until 28 days after the last dose of arct-021. are willing to adhere to contraception requirements if sexually active and/or are of child-bearing potential

inclusion criteria: individuals who: are able to give consent must have completed study arct-021-01 agree to comply with all study visits and procedures only for subjects that will receive arct-021 in this study: are healthy and medically stable are not planning to donate blood or plasma until 28 days after the last dose of arct-021. are willing to refrain from strenuous exercise/activity and alcohol for at least 72 hours prior to study visits and until 28 days after the last dose of arct-021. are willing to adhere to contraception requirements if sexually active and/or are of child-bearing potential

inclusion criteria: individuals who: 1. are able to give consent 2. must have completed study arct-021-01 3. agree to comply with all study visits and procedures only for subjects that will receive arct-021 in this study: 4. are healthy and medically stable 5. are not planning to donate blood or plasma until 28 days after the last dose of arct-021. 6. are willing to refrain from strenuous exercise/activity and alcohol for at least 72 hours prior to study visits and until 28 days after the last dose of arct-021. 7. are willing to adhere to contraception requirements if sexually active and/or are of child-bearing potential

inclusion criteria: individuals who: 1. are able to give consent 2. must have completed study arct-021-01 3. agree to comply with all study visits and procedures only for subjects that will receive arct-021 in this study: 4. are healthy and medically stable 5. are not planning to donate blood or plasma until 28 days after the last dose of arct-021. 6. are willing to refrain from strenuous exercise/activity and alcohol for at least 72 hours prior to study visits and until 28 days after the last dose of arct-021. 7. are willing to adhere to contraception requirements if sexually active and/or are of child-bearing potential